A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

This phase II/III trial tests the addition of daratumumab to chemotherapy for treating patients with newly-diagnosed T-ALL and T-LL. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with daratumumab may kill more cancer cells.

开始日期2026-03-30

申办/合作机构

The Children's Oncology Group Foundation, Inc.

NCT05521087

/ Withdrawn临床1期

A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2Ds) of JNJ-75276617 in combination with a conventional chemotherapy backbone in pediatric and young adult participants with relapsed/refractory acute leukemia harboring histone-lysine N-methyltransferase 2A1 ([KMT2A1], nucleophosmin 1 gene (NPM1), or nucleoporin alterations in Part 1 (Dose Escalation) and to further evaluate safety at the RP2D(s) of JNJ-75276617 in combination with chemotherapy in pediatric and young adult participants with relapsed/refractory acute leukemia harboring KMT2A1, NPM1, or nucleoporin alterations and safety at the RP2D(s) of JNJ-75276617 as monotherapy in a select low burden of disease cohort in Part 2 (Dose Expansion).

开始日期2025-12-26

申办/合作机构

Janssen Research & Development LLC

NCT05700448

/ Not yet recruiting临床3期

A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)

The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.

开始日期2025-12-01

申办/合作机构

基石药业

100 项与培门冬酶相关的临床结果

登录后查看更多信息

100 项与培门冬酶相关的转化医学

登录后查看更多信息

100 项与培门冬酶相关的专利（医药）

登录后查看更多信息

525

项与培门冬酶相关的文献（医药）

2025-10-01·LEUKEMIA RESEARCH

DDGP-based chemoradiotherapy versus radiotherapy alone in newly diagnosed early-stage extranodal NK/T-cell lymphoma: A single-center retrospective analysis

Article

作者: Sun, Jinmiao ; Xie, Ziteng ; Zhang, Mingzhi ; Wang, Di ; Chang, Yu ; Zhang, Lei

To determine the optimal treatment for early-stage extranodal NK/T-cell lymphoma (ENKTL), the efficacy differences between chemoradiotherapy (CRT) and radiotherapy (RT) alone, and between sequential DDGP (dexamethasone, cisplatin, gemcitabine, and pegaspargase) followed by RT (DDGP+RT) versus RT followed by DDGP (RT+DDGP) were investigated. This study compared RT alone versus CRT using DDGP regimen in 189 early-stage ENKTL patients. CRT showed higher objective response rates (95.0% vs 88.0 %, P > 0.05) and significantly improved 10-year PFS (81.3 % vs 54.0 %, P < 0.001) and OS (91.4 % vs 87.3 %, P = 0.029) versus RT alone. DDGP followed by RT (DDGP+RT) achieved superior ORR (98.7 % vs 90.2 %, P = 0.043) and better 10-year PFS in patients with elevated β2-microglobulin (94.4 % vs 57.1 %, P = 0.025) compared to RT followed by DDGP. Multivariate analysis identified RT alone (HR=4.207, P＜0.001), and elevated LDH (HR=4.906, P = 0.012) as poor prognostic factors. CRT sequencing did not significantly affect survival outcomes. These findings demonstrate CRT's superiority over RT alone and suggest β2-MG may guide optimal treatment sequencing in early-stage ENKTL.

2025-10-01·JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Comparing Tolerability and Toxicity of Calaspargase-Pegol and Pegaspargase in Pediatric Leukemia Patients

Article

作者: Redner, Arlene ; Kang, Jinjoo ; Kanukollu, Srivarshini ; Bevinetto, Angelica ; Corless, Rosamarie

As of December 2022, calaspargase-pegol is the standard long-acting asparaginase formulation for patients younger than 22 years of age with acute leukemia. This 3-year retrospective evaluation compared real-world safety and efficacy of calaspargase-pegol versus pegaspargase in pediatric patients. Incidence and severity of hypersensitivity reactions, silent inactivation, and common asparaginase-associated adverse effects were collected. A total of 103 patients were included, of whom 50 received calaspargase-pegol and 58 received pegaspargase. Similar rates of symptomatic hypersensitivity reactions (20% vs. 10.3%; P=0.16) and silent inactivation (16% vs. 5.2%; P=0.18) were seen with calaspargase-pegol versus pegaspargase, respectively. However, 13 patients in the calaspargase-pegol group required conversion to short-acting asparaginase compared with 6 patients in the pegaspargase group (26% vs. 10.3%; P=0.03). Most adverse effects were comparable between the 2 groups, except for a lower rate of hyperbilirubinemia with calaspargase-pegol compared with pegaspargase (34% vs. 58.6%; P=0.01). Overall, no significant differences were found between the formulations in terms of rate of hypersensitivity reactions and silent inactivation. However, calaspargase-pegol did require more conversions to short-acting asparaginase therapy. Additional monitoring and preventative measures should be utilized to prevent calaspargase-pegol–associated adverse effects.

2025-08-01·Blood Vessels, Thrombosis & Hemostasis

Real-world analysis of strategies to prevent thrombosis and bleeding in adults with ALL treated with asparaginase

Article

作者: Miller, Ryan ; Duong, Vu H ; Keng, Michael ; Yelvington, Bradley ; Reed, Daniel R ; Mort, Joseph F ; Locke, Susan C ; Jackson, Clayton ; Brighton, David ; Horton, Bethany ; Mautner, Benjamin ; Wolfe, Heather ; El Chaer, Firas ; Lawson, Justin ; Shallis, Rory M ; Ghamsari, Farid ; Pierce, Eric ; LeBlanc, Thomas W ; Abernathy, Karin ; Walsh, Katherine ; Patel, Imari ; D'Souza, Darren ; Infield, Jordan ; Allen, Cecily ; Dholaria, Bhagirathbhai

The prognosis of adult patients with acute lymphoblastic leukemia (ALL) has improved with the incorporation of pediatric-inspired regimens that contain PEGylated asparaginase (PEG-Asp). However, PEG-Asp administration is associated with an increased rate of thrombosis. Data regarding the benefits of antithrombin (AT) repletion and prophylactic anticoagulation in adults receiving PEG-Asp-based regimens are limited. We performed a retrospective study to evaluate the rates of induction thrombosis and bleeding among adults receiving ALL therapy containing Asp at 6 academic centers in the United States. Of 233 patients who met the inclusion criteria, 98.3% received PEG-Asp. Ninety-six patients (41.2%) had their AT levels monitored, 58 patients (24.9%) received AT repletion, and 41 patients (17.6%) received prophylactic anticoagulation. Thirty-two patients (13.7%) experienced thrombotic events, with half (53.1%) being line-associated thromboses. In multivariate analysis, the odds of thrombosis did not differ between patients who received AT monitoring, AT repletion, or prophylactic anticoagulation. The odds of thrombosis were 4 times higher for patients with peripherally inserted central catheters than for those with other types of central lines (odds ratio, 4.112; 95% confidence interval, 1.622-10.427; P = .01). Thrombotic risk did not differ based on age, cumulative Asp dose, type of steroid administered, or whether transfusions were performed. Bleeding occurred in 12 patients (5.2%), and major bleeding occurred in 8 patients (3.4%). The odds of bleeding did not increase in the patients who received prophylactic anticoagulation. Our study brings into question whether prophylactic AT repletion and anticoagulation are beneficial strategies for reducing PEG-Asp-associated thrombosis, and large randomized prospective studies are needed.

项与培门冬酶相关的新闻（医药）

2025-08-13

·EINPresswire

'Just keep smiling': 5-year-old beats uncommon type of leukemia following rare allergy to chemo

Hillary Lofton-Mosley had planned out every detail of her dream wedding in Jamaica, down to her 2-year-old daughter, Harlow, serving as the flower girl. But just a couple weeks before the big day in September 2022, as she was packing suitcases for the trip, she noticed Harlow had developed a cough. Her typical upbeat demeanor was off, too. “You can feel when something’s wrong with your child,” Lofton-Mosley said. “I knew something was different about her.” At first, Harlow’s care team thought she had a viral infection that would clear up on its own. When the cough didn’t improve, Lofton-Mosley pushed for an X-ray. The doctor thought there was a chance Harlow had a heart murmur and said they could follow up with her care after the wedding. After the family landed in Jamaica, Harlow became lethargic and didn’t want to play with her cousins. She was too tired to walk down the aisle; Lofton-Mosley’s mother had to carry her. On the plane ride back with her grandmother, Harlow began having troubling coughing fits. “My mom was like, ‘Something's not right about this child,’” Lofton-Mosley said. “As soon as I touch the soil, I'm taking her to the doctor.” Harlow’s pediatrician recommended she see a pediatric cardiologist at University of Chicago Medicine Comer Children’s Hospital because of the suspected heart murmur. Lofton-Mosley and her now-husband, Gerald, cut their honeymoon short and flew back to their home in Northwest Indiana. ‘Harlow has cancer’ Lofton-Mosley said the day of Harlow’s first appointment at Comer Children’s in October 2022 was mostly a blur, aside from a blood test and a few words from the cardiologist. It was the worst day of Lofton-Mosley’s life. “I remember the doctor looking at me, clasping his hands and saying, ‘Miss Lofton, there's no easy way to say this: Harlow has cancer,’” she said. Harlow’s care team diagnosed her with T-cell acute lymphoblastic leukemia (T-ALL), a cancer of the bone marrow and blood. Leukemia can occur at any age, but it is most commonly diagnosed in children between 2 and 6 years old. Pediatric leukemia is the most common type of childhood cancer , but T-ALL is one of the less common strains, said Gabrielle Lapping-Carr, MD , a pediatric hematologist/oncologist at Comer Children’s and one of Harlow’s doctors. When children have leukemia, their bone marrow makes white blood cells that do not mature properly. These unhealthy cells rapidly reproduce, crowding out the healthy bone marrow cells that produce infection-fighting white blood cells, red blood cells and platelets. “I always tell patients that almost every leukemia patient is diagnosed with something else first, whether it's a cold or a skin infection, or even a bruise,” Lapping-Carr said. “Everybody assumes their child has something else before they get a diagnosis of cancer, and that's OK. "We have lots of wonderful therapies to take care of children with leukemia and I don’t want people to lose sleep over it having been called something else first. The important part is they did the good work to bring in their sick child to be evaluated.” Like Harlow, many children with T-ALL present with symptoms like fatigue and anemia. Some may also have masses in their chests, along with breathing problems that resemble pneumonia. Harlow and her mom would have to stay at Comer Children’s for the next few weeks. Harlow’s oncology team determined she had a good prognosis, and they were able to assure Lofton-Mosley that they felt confident in treating her daughter. The family took comfort in knowing that Comer Children’s leukemia specialists offer the latest investigational therapies, as well as established treatments for all types of leukemia in children, and they do everything possible to minimize their effects on a child’s health. After allergic reaction to chemo, remission After the initial inpatient stay, Lofton-Mosley drove Harlow to the hospital for regular chemotherapy infusions. But at the beginning of one of her early treatments, doctors made a frightening discovery: Harlow had an uncommon allergy to one of her chemo medications, PEG-asparaginase. During an infusion, Harlow unexpectedly began to convulse. Her team quickly had to admit and intubate her, which broke her mother’s heart to watch. Once they identified the chemo allergy, Harlow’s doctors switched her treatment regimen: more frequent doses of a shorter-acting version of the infusion, followed by oral chemo. Harlow completed the 28-month-long regimen in February. On Lofton-Mosley’s 41st birthday in February, Harlow rang the bell in Comer Children’s to signify the end of her cancer treatment. Friends, family and members of her care team cheered and used bubble machines around her to help celebrate. Lofton-Mosley said Harlow was a trooper through it all, even when taking her at-home oral chemo pills. “Crushing up those pills was no fun,” she said. “She doesn’t like it, but she acts like she does. I don't even think adults could do that. But she does it.” From left: Hillary Lofton-Mosley, her daughter Harlow and husband Gerald. Cherishing every moment Now 5 years old, Harlow is healthy and back to her smiling, upbeat self. She and her family enjoy cooking together and watching shows like “Family Feud.” “I would tell other families going through this: Just keep smiling,” Lofton-Mosley said. “That's all you can do, because she smiled the whole time. And that, to me, is the biggest blessing.” Lapping-Carr said she was always impressed by how much strength Lofton-Mosley brought to the table, which allowed Harlow to “not miss out on being a kid.” “She was always still having fun every moment that she could,” Lapping-Carr said. “I think those of us who work with kids do so because the kids still want to have fun despite everything they are going through. That is what makes our job easier, and you were definitely able to see that with Harlow.” Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床3期临床结果

2025-07-04

·恒瑞医药

2025 ICML口头报告｜恒瑞医药“双艾”组合联合治疗NK/T细胞淋巴瘤最新研究数据公布

第18届国际恶性淋巴瘤会议(2025 ICML)于2025年近日在瑞士卢加诺举行。作为全球最大的恶性淋巴瘤国际会议之一，大会云集了全球顶级的淋巴瘤领域专家学者，分享淋巴瘤基础、临床、转化医学、新药开发等最前沿的研究成果，共同推动全球淋巴瘤诊疗事业的发展。本次大会上，由中山大学肿瘤防治中心的李志铭教授、复旦大学附属肿瘤医院的陶荣教授和复旦大学附属眼耳鼻喉科医院的丁浩教授作为共同PI开展的一项卡瑞利珠单抗联合低剂量阿帕替尼和培门冬酶(CAPA)序贯放疗治疗初发Ⅰ/Ⅱ期NK/T细胞淋巴瘤患者的研究入选口头汇报(摘要号：063)[1]，该研究曾在2023年欧洲血液学协会大会（EHA）大会上首次亮相，报告了治疗结束后的完全缓解率(CRR)和客观缓解率(ORR)[2]，时隔两年，这项研究迎来了长期生存数据结果。复旦大学附属肿瘤医院刘传绪教授在卢加诺现场进行了大会报告。2025 ICML现场图：刘传绪教授进行口头报告01研究背景目前国内对早期NK/T细胞淋巴瘤(IE，IIE期)以门冬酰胺化疗和放疗的有序结合形成序贯治疗模式初步显示较好的疗效，2年的总生存(OS)率达到80%[3]，提高了患者长期生存率。但门冬酰胺酶副作用多，与化疗药物的联合使用增加了不良反应的发生率[4-6]，部分患者不能耐受而限制了其广泛使用。因此如何改善以门冬酰胺酶为基础的治疗的安全性，从而改善患者的长期预后，仍是目前临床面临的主要课题。卡瑞利珠单抗是一种PD-1抑制剂，阿帕替尼是血管内生长因子受体-2(VEGFR-2)高效、选择性抑制剂，卡瑞利珠单抗联合阿帕替尼的治疗方式已在多种实体瘤和淋巴瘤中显示出抗肿瘤活性和可耐受性[7-11]。本研究将PD-1抗体卡瑞利珠单抗联合低剂量阿帕替尼和培门冬酶(CAPA)序贯放射治疗，尝试用于治疗I-II期NK/TCL患者，观察其有效性和安全性。02研究方法该研究为一项前瞻性、多中心、单臂研究，纳入标准为：根据WHO2016标准确诊的初发NK/T细胞淋巴瘤患者，至少有1个可测量病灶，Lugano 2014分类为IE/IIE期，年龄18~80岁，ECOG PS评分为0~2分。患者共接受4个周期的治疗，以21天为周期，第1天静脉注射卡瑞利珠单抗200 mg，肌肉注射培门冬酶2000 U/m2，阿帕替尼250 mg，QD。全身治疗后，两周内给予总剂量为50~56 Gy的扩大野放疗。主要终点为放疗后(24周)的CRR。次要终点包括24周(24W) ORR、2年OS、2年无进展生存期(PFS)和安全性。图1.研究设计03研究结果1临床疗效2020年5月至2022年10月，本研究共纳入61例患者，中位年龄52岁，其中男性37例(60.7%)，IIE期29例(47.5%)，50例患者完成了4周期(12W)全身治疗后的疗效评估，12W CRR为70.0%，12W ORR为82.0%。53例患者在放疗后(24W)完成了疗效评估，24W CRR为88.9%(48/54)，ORR为92.6%(50/54)。图2. 患者缓解情况截至2025年2月，中位随访时间42.2个月(34.7-46.1)，2年PFS率为83.3%(95% CI：70.4-91.0)，2年OS率达到88.9%(95% CI：76.9-94.9)。图3. PFS(左)和OS(右)的K-M曲线12W时获得完全缓解和部分缓解(CR+PR)的患者，2年PFS率达到90.2%(95% CI：76.1-96.2)，12W时疾病稳定和疾病进展(SD+PD)的患者2年PFS率为55.6%(95% CI：20.4-80.5)(P＜0.05)。12W时CR+PR患者的2年OS率为95.1%(95% CI：81.9-98.8)，12W时SD+PD患者2年OS率为66.7%(95% CI：28.2-87.8)(P＜0.05)。安全性方面整体可控。图4. 亚组分析的PFS(左)和OS(右)04研究结论卡瑞利珠单抗联合低剂量阿帕替尼和培门冬酶序贯放疗治疗初发I/II期NK/T细胞淋巴瘤患者具有令人鼓舞的疗效和安全性，能够大幅降低化疗带来的血液学毒性，该方案有望作为传统治疗的可行替代方案。参考文献：[1] Camrelizumab plus low-dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II natural killer/T-cell lymphoma: a multicenter phase II study.18-ICML Oral 063.[2] Camrelizumab plus low-dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II natural killer/ T-cell lymphoma: a prospective multicenter single-arm study.2023 EHA P1119.[3] Tse E, Zhao WL, Xiong J, Kwong YL. How we treat NK/T-cell lymphomas. J Hematol Oncol. 2022;15(1):74. Published 2022 Jun 3.[4] Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973-2980.[5] Jing XM, Zhang ZH, Wu P, et al. Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma. Leuk Res. 2016;47:26-31. [6] Zhang L, Wang Y, Li X, et al. Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study. Int J Cancer. 2021;148(6):1470-1477.[7] Mao, L., et al., Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial. JAMA Oncol, 2023. 9(8): p. 1099-1107.[8] Ding, X., et al., Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study. J Clin Oncol, 2023. 41(14): p. 2571-2582.[9] Yu, J.H., et al., Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study. Lancet Oncol, 2024. 25(7): p. 843-852.[10] Lan, C., et al., Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial. J Clin Oncol, 2020. 38(34): p. 4095-4106.[11] Liu, Y., et al., Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study. Front Immunol, 2023. 14: p. 1128172.声明：1.本新闻旨在分享学术前沿动态，仅供医疗卫生专业人士基于学术目的参阅，非广告用途。2.恒瑞医药不对任何药品和/或适应症作推荐。3.本新闻中涉及的信息仅供参考，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。撰稿：肿瘤中央医学事务部排版：程梦真责编：李玉莹往期精选| 研发创新 |恒瑞创新药瑞坦宁®获批，用于预防成人高度致吐性化疗引起的急性和迟发性恶心呕吐| 国际化 |恒瑞医药再次与德国默克集团达成合作，推进辅助生殖领域口服GnRH拮抗剂商业化落地恒瑞医药与默沙东就Lp(a)抑制剂HRS-5346签订独家许可协议| 重磅奖项 |捷报！恒瑞医药创新药海曲泊帕乙醇胺片（恒曲®）专利荣获中国专利金奖喜报！恒瑞医药荣获2023年度国家科技进步奖| 社会公益 |“健康中国行·重走长征路”项目启动仪式圆满举行！恒瑞提供公益支持，助力健康中国恒瑞医药集团向中国扶贫基金会捐赠3000万设立“健康帮扶基金”

临床2期细胞疗法临床结果

2025-05-12

·ioncology

18-ICML·抢先看丨汇聚中国风采！第18届国际恶性淋巴瘤会议17项口头报告及30项壁报全景呈现

由瑞士肿瘤研究所基金会（IOR）主办的第18届国际恶性淋巴瘤会议（18-ICML）将于2025年6月17日至21日在瑞士卢加诺会议中心（Palazzo dei Congressi）召开。作为全球血液肿瘤学领域最具影响力的两年一度的学术盛会，本届会议预计汇聚来自全球的千余名血液学家、临床肿瘤学家、放射肿瘤学家、儿科医生、病理学家及淋巴瘤研究领域的前沿学者，共同探讨疾病机制、转化医学进展及临床诊疗创新。在本次盛会中，中国学者以丰富的学术成果为会议增光添彩，共呈现17项口头报告及30项壁报展示（截至2025年5月12日）。《肿瘤瞭望-血液时讯》特此系统梳理研究成果，旨在为临床医师及科研工作者提供学术风向标，助力我国淋巴瘤诊疗水平的提升。口头报告（ORAL）*汇报时间均为当地时间1淋巴瘤放射治疗研讨会LYMPHOMA RADIOTHERAPY WORKSHOP中文题目：现今应该采用哪种全身治疗方案？英文题目：Which systemic regimen should be used today?发言人：中山大学附属肿瘤医院蔡清清教授时间：6.17 16:15地点：Cinema Corso中文题目：现代系统性治疗背景下早期阶段的放射剂量与照射体积英文题目：Radiation doses and volumes in early stages with modern systemic therapy发言人：Shunan Qi（北京）时间：6.17 16:30地点：Cinema Corso2聚焦专场-进行中的临床试验“FOCUS ON…” SESSIONS-ONGOING TRIALS中文题目：GUIDANCE-02：一项关于遗传亚型指导的免疫化疗在弥漫大B细胞淋巴瘤中的多中心随机III期研究英文题目：GUIDANCE-02: A multi-center randomized phase 3 study of genetic subtype-guided immunochemotherapy in diffuse large B-cell lymphoma摘要号：OT5发言人：上海交通大学医学院附属瑞金医院赵维莅教授时间：6.18 17:40地点：Cinema Corso3儿童淋巴瘤PEDIATRIC LYMPHOMAS中文题目：中国T细胞淋巴母细胞淋巴瘤儿科患者中融合基因的发生频率及其临床影响英文题目：Frequency of fusion genes and their clinical impacts in Chinese pediatric patients with T cell lymphoblastic lymphoma摘要号：36发言人：高博医学（血液病）北京研究中心北京高博博仁医院医疗张永红教授时间：6.19 15:55地点：Auditorium, West Campus USI中文题目：53例复发或难治性儿童ALK阳性间变性大细胞淋巴瘤的临床分析英文题目：Clinical analysis of 53 cases of relapsed or refractory childhood ALK + anaplastic large cell lymphoma摘要号：38发言人：高博医学（血液病）北京研究中心王凯教授时间：6.19 16:15地点：Auditorium, West Campus USI4套细胞淋巴瘤MANTLE CELL LYMPHOMA中文题目：奥布替尼、来那度胺联合利妥昔单抗作为套细胞淋巴瘤一线治疗的新型三联方案：POLARIS多中心II期研究的最终结果英文题目：Novel Triplet Combination of Orelabrutinib, Lenalidomide, and Rituximab as Frontline Therapy for Mantle Cell Lymphoma: Final Results of POLARIS Multicenter Phase II Study摘要号：48发言人：天津医科大学肿瘤医院宋拯教授时间：6.19 16:15地点：Room A.bradcast in Ginema Corso5早期临床试验EARLY CLINICAL TRIALS中文题目：DZD8586在经共价或非共价BTK抑制剂及BTK降解剂治疗后的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中的I/II期研究英文题目：Phase 1/2 Studies of DZD8586 in CLL/SLL Patients after Covalent or Non-covalent BTKInhibitors and BTK Degraders摘要号：146发言人：南京医科大学第一附属医院（江苏省人民医院）李建勇教授时间：6.19 17:35地点：Auditorium, West Campus USI7NK/T细胞淋巴瘤NK/T-CELL LYMPHOMA中文题目：SHR2554（一种口服性EZH2抑制剂）在复发或难治性外周T细胞淋巴瘤中的关键性研究英文题目：A Pivotal Study of SHR2554, An Oral Inhibitor Against Enhancer of Zeste Homolog 2 (EZH2), in Relapsed or Refractory (r/r) Peripheral T-cell Lymphoma (PTCL)摘要号：61发言人：北京大学肿瘤医院宋玉琴教授时间：6.20 09 :15地点：Room B,broadcast in Marquee Parco Ciani中文题目：帕博利珠单抗联合放疗治疗新诊断早期自然杀伤/T细胞淋巴瘤虚弱患者的Ⅱ期临床试验（IELSG50）英文题目：A Phase II Trial of Pembrolizumab Concurrent with Radiotherapy for Frail Patients with Newly Diagnosed Early-stage Natural Killer/T-cell Lymphoma (IELSG50)摘要号：62发言人：上海交通大学医学院附属瑞金医院赵维莅教授时间：6.20 09 :30地点：Room B,broadcast in Marquee Parco Ciani中文题目：卡瑞利珠单抗联合低剂量阿帕替尼及培门冬酶后行放疗治疗新诊断Ⅰ/Ⅱ期自然杀伤/T细胞淋巴瘤：一项多中心Ⅱ期研究英文题目：Camrelizumab plus low-dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II natural killer/T-cell lymphoma: a multicenter phase II study摘要号：63发言人：Chuanxu Liu（上海）时间：6.20 09 :45地点：Room B,broadcast in Marquee Parco Ciani8淋巴瘤研究：来自中国与欧洲的最新进展LYMPHOMA RESEARCH: NEWS FROM CHINA AND EUROPE中文题目：弥漫性大B细胞淋巴瘤治疗进展：中国视角亮点英文题目：Advances in DLBCL Management: Highlights from China摘要号：UCLI1发言人：哈尔滨血液病肿瘤研究所赵东陆教授时间：6.20 14:35地点：Polivalente room,East Campus USI中文题目：液体活检技术在淋巴瘤领域的最新进展英文题目：State-of-the-art of Liquid Biopsy in Lymphoma摘要号：UCLI3发言人：Meng Wu（北京）时间：6.20 14:55地点：Polivalente room,East Campus USI中文题目：中国新型药物在惰性淋巴瘤治疗中的国际应用概述英文题目：International Overview of Chinese Novel Drugs in Indolent Lymphoma摘要号：UCLI5发言人：吉林大学白求恩第一医院白鸥教授时间：6.20 16:15地点：Polivalente room,East Campus USI9新型药物NEW DRUGS中文题目：一项评估选择性 EZH2 抑制剂-XNW5004 在复发/难治性非霍奇金淋巴瘤受试者中安全性和有效性的 1/2 期研究英文题目：A Phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/ refractory non-Hodgkin lymphoma摘要号：95发言人：中国医学科学院血液病医院（中国医学科学院血液学研究所）邱录贵教授时间：6:21 10:30地点：Room A10T细胞淋巴瘤的生物学与治疗BIOLOGY AND THERAPY OF T-CELL LYMPHOMAS中文题目：他泽司他联合Amdizalisib 治疗具有不同基因组特征的复发或难治性外周T细胞淋巴瘤患者：一项Ⅱ期研究结果英文题目：Tazemetostat plus Amdizalisib in Relapsed/Refractory Peripheral T-cell Lymphoma Patients with Diverse Genomic Signatures: Results from a Phase 2 Study摘要号：163发言人：上海交通大学医学院附属瑞金医院程澍教授时间：6:21 09:55地点：Room B中文题目：林普利塞联合CHOP方案治疗新诊断外周T细胞淋巴瘤：一项单臂、开放标签、多中心Ⅰb/Ⅱ期研究（LINCH试验）英文题目：Linperlisib Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma: A Single-Arm,Open-Lable, Multi-Center Phase Ib/II Study (LINCH Trial)摘要号：165发言人：中山大学附属肿瘤医院蔡清清教授时间：6.21 10:15地点：Room B中文题目：戈利昔替尼（一种选择性JAK1抑制剂）作为一线全身治疗后外周T细胞淋巴瘤患者维持治疗的疗效更新：Ⅱ期研究（JACKPOT26）进展英文题目：Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with PTCLs after First-line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)摘要号：167发言人：浙江大学医学院附属第一医院金洁教授时间：6.21 10:35地点：Room B壁报展示（POSTER）1淋巴瘤生物学Lymphoma biology中文题目：稳定化MYCT58A突变绕过T细胞辅助作用驱动生发中心B细胞淋巴瘤发生英文题目：Stabilized MYCT58A Bypasses T-Cell Help to Fuel Germinal Center B-Cell Lymphomagenesis摘要号：171作者：Baizhi Chen2淋巴瘤遗传学Lymphoma genetics中文题目：EGR2基因突变预示接受布鲁顿酪氨酸激酶抑制剂治疗的慢性淋巴细胞白血病患者预后不良英文题目：EGR2 mutations Confer Poor Prognosis in Chronic Lymphocytic Leukemia Treated with Bruton Tyrosine Kinase Inhibitors摘要号：176作者：Huayuan Zhu中文题目：结外受累滤泡性淋巴瘤的临床特征与分子异质性分析英文题目：Clinical characteristics and molecular heterogeneity in Follicular Lymphoma with extranodal involvement摘要号：178作者：赵维莅3淋巴瘤分类Lymphoma classification中文题目：全基因组测序揭示三种具有不同起源细胞特征和患者预后的滤泡性淋巴瘤亚型英文题目：Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell-of-origin and patient outcomes摘要号：193作者：Weicheng Ren中文题目：多组学解析EB病毒驱动的结外NK/T细胞淋巴瘤进展中的异质性、代谢重塑及肿瘤细胞图谱英文题目：Multi-omics dissection of EBV-driven heterogeneity, metabolic remodeling, and tumor cellular landscape in ENKTL progression摘要号：195作者：梁金花4慢性淋巴细胞白血病Chronic lymphocytic leukemia中文题目：癌前生发中心B细胞的免疫监视机制研究英文题目：Immunosurveillance of Precancerous Germinal Center B Cells摘要号：202作者：LINGLING ZHANG中文题目：空间组学与单细胞多组学揭示原发性中枢神经系统淋巴瘤与弥漫大B细胞淋巴瘤的巨噬细胞异质性英文题目：Spatial and Single-Cell Multi-omics Reveal Macrophage Heterogeneity between Primary CNS Lymphoma (PCNSL) and Diffuse Large B-Cell Lymphoma (DLBCL)摘要号：206作者：Liang Hong5边缘区与淋巴浆细胞性淋巴瘤Marginal zone and lymphoplasmacytic lymphoma中文题目：奥布替尼联合奥妥珠单抗（O2方案）一线治疗边缘区淋巴瘤的疗效、安全性及合理性：前瞻性队列研究英文题目：The efficacy, safety and rationality of Orelabrutinib plus Obinutuzumab (O2) in systemic treatment-naïve marginal zone lymphoma: a prospective cohort study摘要号：255作者：Jiadai Xu6套细胞淋巴瘤Mantle Cell Lymphoma中文题目：非结节性套细胞淋巴瘤未必等同于惰性MCL：LEO队列研究的临床观察英文题目：Leukemic non-nodal mantle cell lymphoma (nnMCL) is not necessarily equivalent to indolent MCL: A report from the LEO Cohort Study.摘要号：271作者：Tony Zibo Zhuang7侵袭性B细胞淋巴瘤——一线临床试验Aggressive B-cell lymphomas-first line clinical trials中文题目：新型ZCR方案（泽布替尼、西达本胺、利妥昔单抗）±CHOP方案在双表达弥漫大B细胞淋巴瘤一线治疗中展现显著疗效英文题目：Novel ZCR (Zanubrutinib, Chidamide, Rituximab) ± CHOP Regimen Demonstrates Promising Efficacy in Frontline Treatment of Double-Expressor Diffuse Large B-Cell Lymphoma摘要号：284作者：Zhiming Li中文题目：维泊妥珠单抗、泽布替尼联合利妥昔单抗（Pola-ZR方案）治疗初治老年及虚弱DLBCL患者的疗效与安全性：前瞻性Ⅱ期临床试验英文题目：Efficacy and Safety of Polatuzumab Vedotin, Zanubrutinib and Rituximab (Pola-ZR) in Untreated Elderly and Frail DLBCL Patients: A Prospective Phase 2 Clinical Trial摘要号：285作者：Yuhong Ren8侵袭性B细胞淋巴瘤治疗结果Aggressive B-cell lymphomas outcomes中文题目：POLARIX研究5年亚组分析：亚洲未经治疗的DLBCL患者中Pola-R-CHP方案的疗效获益验证英文题目：Five-Year Analysis of an Asia Subpopulation with Previously Untreated DLBCL Confirms Pola-R-CHP Benefit on Outcomes: The POLARIX Study摘要号：288作者：宋玉琴中文题目：中国大规模真实世界研究：不同基因亚型弥漫大B细胞淋巴瘤的临床实践模式与预后差异英文题目：Clinical practice pattern and outcomes in DLBCL with distinct genetic subtypes: a large-scale real-world study from China摘要号：294作者：许彭鹏9复发/难治性侵袭性B细胞淋巴瘤：临床试验Relapsed/refractory aggressive B-cell lymphomas: clinical trials中文题目：分子亚型指导的R-MINE+X方案治疗复发/难治性弥漫大B细胞淋巴瘤：单臂开放标签多中心Ⅱ期研究英文题目：Molecular Subtype-Guided R-MINE+X Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Single-arm, Open-label, Multicenter Phase II Study摘要号：317作者：梁金花10中枢神经系统淋巴瘤CNS Lymphomas中文题目：MEDZ-R方案治疗新诊断原发性中枢神经系统淋巴瘤的多中心前瞻性Ⅱ期临床试验英文题目：A multi-center prospective phase II clinical trial of the MEDZ-R regimen for the treatment of newly diagnosed primary central nervous system lymphoma摘要号：332作者：li Zou中文题目：利妥昔单抗联合大剂量甲氨蝶呤及奥布替尼作为新诊断原发性中枢神经系统淋巴瘤的诱导治疗方案英文题目：Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma摘要号：333作者：Wenrong Huang中文题目：奥布替尼联合抗PD-1抗体与福莫司汀治疗新诊断原发性中枢神经系统淋巴瘤的Ⅰ/Ⅱ期研究英文题目：A Phase I/II Study of Orelabrutinib Combined with Anti-PD-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)摘要号：334作者：Wanyue Zhao11原发性纵隔淋巴瘤Primary mediastinal lymphoma中文题目：替雷利珠单抗联合R-CHOP方案治疗初治原发性纵隔大B细胞淋巴瘤：前瞻性Ⅱ期临床试验英文题目：Anti-PD-1 antibody (Tislelizumab) combined with R-CHOP for the treatment of previously untreated primary mediastinal B-cell lymphoma: A prospective phase II study摘要号：347作者：Wen Shu juan12霍奇金淋巴瘤Hodgkin Lymphoma中文题目：老年霍奇金淋巴瘤治疗格局演变与预后分析：中国15年多中心回顾性研究揭示新型疗法影响英文题目：Evolving Treatment Landscape and Outcomes in Elderly Hodgkin Lymphoma: A 15-Year Multicenter Retrospective Analysis from China Highlighting the Impact of Novel Therapies摘要号：366作者：赵培起13儿科淋巴瘤Pediatric lymphomas中文题目：中国南方真实世界研究：PD-1抗体单药及联合方案治疗儿童淋巴瘤的疗效与安全性英文题目：real world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients in South China摘要号：375作者：Jia Zhu中文题目：儿童、青少年及青年霍奇金淋巴瘤长期生存者的晚期并发症与生活质评估英文题目：Late Complications and Quality of Life in Long-Term Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma摘要号：377作者：Linnan Wu14NK/T细胞淋巴瘤NK/T-cell Lymphomas中文题目：EGF-JAK/STAT通路突变对血管免疫母细胞性T细胞淋巴瘤的预后及功能影响研究英文题目：Prognostic and Functional Impact of EGF-JAK/STAT Pathway Mutations in Angioimmunoblastic T-cell Lymphoma (AITL)摘要号：384作者：DACHUAN HUANG中文题目：全血EB病毒DNA载量在血管免疫母细胞性T细胞淋巴瘤中的预后价值分析英文题目：The prognostic role of whole blood Epstein‑Barr virus DNA load in angioimmunoblastic T-cell lymphoma摘要号：385作者：Yi Zhong中文题目：阿扎胞苷联合西达本胺及CHOP方案对比CHOP方案治疗初治外周T细胞淋巴瘤的Ⅱ期研究英文题目：A phase II study of azacitidine and chidamide plus CHOP versus CHOP in previously untreated patients with peripheral T-cell lymphoma摘要号：391作者：Chong Wei中文题目：西达本胺联合阿扎胞苷、米托蒽醌脂质体及泼尼松（CAMP方案）治疗TFH来源的初治外周T细胞淋巴瘤英文题目：Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma摘要号：392作者：Huimin Liu中文题目：PD-1抑制剂信迪利单抗联合培门冬酶与安罗替尼治疗Ⅳ期NK/T细胞淋巴瘤的疗效与安全性：多中心前瞻性研究英文题目：A Multi-center, Prospective Study of the Efficacy and Safety of PD-1 Antibody Sintilimab in Combination With Pegaspargase and Anlotinib in Stage IV NKTCL Patients摘要号：400作者：Rong Tao15多发性骨髓瘤Multiple Myeloma中文题目：塞利尼索联合硼替佐米、来那度胺及地塞米松治疗高危初治多发性骨髓瘤的单臂多中心观察性研究英文题目：A single-arm, multi-center, observational study of Selinexor combined bortezomib, lenalidomide, and dexamethasone in high-risk newly diagnosed multiple myeloma(NDMM) 摘要号：403作者：Yuping Zhong16液体活检Liquid Biopsy中文题目：动态ctDNA监测揭示的分子特征：不同基因亚型弥漫大B细胞淋巴瘤的预后价值、临床病程及克隆演化规律英文题目：Molecular features encoded in the dynamic ctDNA monitoring reveal prognostic value, different clinical courses and clone evolution for different genetic subtypes of DLBCL摘要号：422作者：梁金花17新型组合Novel compounds中文题目：泽布替尼联合来那度胺治疗复发/难治性弥漫大B细胞淋巴瘤的Ⅰ期临床研究分析英文题目：Analysis of a Phase 1 Study of Zanubrutinib (Zanu) + Lenalidomide (Len) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)摘要号：439作者：张会来18新型细胞疗法New cellular therapies中文题目：携带OX40信号的CAR-T疗法驱动CD4+T细胞克隆扩增并克服B细胞淋巴瘤免疫抑制微环境：Ⅰ期临床试验英文题目：CAR-T Therapy with OX40 Signaling Drives Clonal Expansion of CD4+ T Cells and Overcomes Immunosuppressive Microenvironment in B-Cell Lymphoma: A Phase I Trial摘要号：466作者：Ling-Shuang Sheng*因官网尚未公布详细壁报信息，可能出现错漏，敬请谅解《肿瘤瞭望-血液时讯》将全程追踪并深度解析18-ICML的学术动态与会议进展，诚邀广大血液肿瘤领域临床工作者及研究人员持续关注本刊后续报道！（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

放射疗法临床2期

100 项与培门冬酶相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05387	培门冬酶	L01XX24	DB00059

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
淋巴瘤	日本	Nihon Servier Co., Ltd.	2023-06-26
超敏反应	美国	Servier Pharmaceuticals LLC	2019-01-03
急性淋巴细胞白血病	美国	Servier Pharmaceuticals LLC	1994-02-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
前体B细胞急性淋巴细胞白血病	临床3期	美国	Servier Pharmaceuticals LLC	2017-03-03
前体B细胞急性淋巴细胞白血病	临床3期	加拿大	Servier Pharmaceuticals LLC	2017-03-03
前体T淋巴细胞白血病淋巴瘤	临床3期	美国	Servier Pharmaceuticals LLC	2017-03-03
前体T淋巴细胞白血病淋巴瘤	临床3期	加拿大	Servier Pharmaceuticals LLC	2017-03-03
淋巴母细胞淋巴瘤	临床2期	美国	Shire Plc	2012-06-01
淋巴母细胞淋巴瘤	临床2期	加拿大	Shire Plc	2012-06-01
复发性儿童急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
复发难治性急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
难治性成人急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
非霍奇金淋巴瘤	临床1期	美国	Enzon Pharmaceuticals, Inc.	2006-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05774028 (EHA2025) 人工标引	临床2期	结外NK-T细胞淋巴瘤	20	Pegaspargase+Gemcitabine+Etoposide+Mitoxantrone hydrochloride liposome+Dexamethasone (P-GEMD) regimen	窪鏇窪醖築壓遞憲選簾(選蓋觸顧糧鏇積齋膚夢) = 壓壓製壓醖窪鹽膚獵構衊夢積範夢襯構鏇鬱繭 (蓋夢膚蓋顧鹹艱顧獵願 ) 更多	积极	2025-05-14
CAMPUS ALL (EHA2025)	N/A	急性淋巴细胞白血病	90	PEG-ASP 1000 UI/m^2	獵膚醖壓築窪範蓋製淵(壓襯齋範夢鏇壓醖艱鹽) = Coagulopathy occurred in 26% of cases (grade ≥3, 6%), without significant differences in the 3 groups 襯齋淵窪鏇構選鑰糧製 (艱構鬱憲鑰廠顧鹽觸積 ) 更多	-	2025-05-14
PS1386 (EHA2025)	N/A	前体T淋巴细胞白血病淋巴瘤 BCL-2	13	Venetoclax	鑰鬱淵積糧積衊齋遞鹹(蓋網積襯糧獵鹹窪範餘) = 84% 襯觸範鏇淵餘鹽積窪願 (餘製齋願製獵網淵鹽範 ) 更多	-	2025-05-14
				Tucidinostat
GIMEMA LAL1913 (EHA2025)	临床2期	淋巴母细胞淋巴瘤	50	Pegaspargase-based treatment	範網鏇築鹽積鹽衊鏇窪(網醖製憲壓襯獵夢願壓) = A better 5-year DFS was observed in patients ≤40 years (80%) when compared with those >40 (56%) 簾壓艱積鹹製淵積憲壓 (獵艱淵製築範願膚選糧 ) 更多	积极	2025-05-14
				High cumulative dose (HCD) steroids
Caall-F01 (ASH2024)	N/A	急性淋巴细胞白血病	2,032	Pegaspargase (Arm A (two-infusion scheme))	淵製齋鏇願選鏇夢簾艱(淵築窪網鹽醖鬱範齋觸) = 鑰積網衊願鬱醖鑰顧選製淵糧願蓋繭鑰觸窪遞 (鬱顧糧衊膚衊觸鬱壓窪 )	积极	2024-12-08
				Pegaspargase (Arm B (one-infusion scheme))	淵製齋鏇願選鏇夢簾艱(淵築窪網鹽醖鬱範齋觸) = 鹹窪選餘簾醖鹽餘鬱蓋製淵糧願蓋繭鑰觸窪遞 (鬱顧糧衊膚衊觸鬱壓窪 )
NCT06376721 (ASH2024)	临床1期	结外NK-T细胞淋巴瘤二线	6	培门冬酶+林普利塞+卡瑞利珠单抗	醖蓋齋鹹網構觸製鹹齋(膚獵膚構蓋鏇齋獵艱廠) = 衊餘製積鏇鏇築積鏇簾夢窪鑰廠遞繭鹹獵繭鬱 (蓋鏇遞選鬱觸艱範膚窪 ) 更多	积极	2024-11-05
SOHO2024	N/A	急性淋巴细胞白血病	-	Pegaspargase	膚構窪繭顧廠製願膚艱(壓鹹鹹艱夢窪鹹糧窪積) = 4% during the induction phase, 1 patient during the consolidation phase 壓夢齋糧壓淵鬱蓋積餘 (窪鬱鹹艱觸廠願繭艱糧 ) 更多	-	2024-09-04
				Erwinia asparaginase
NCT03792256 (CTgov)	临床1期	复发性成人急性淋巴细胞白血病 \| T细胞淋巴瘤 \| 急性白血病 ... 更多	12	ARAC (Stratum 1 With 50 mg/m^2)	繭鹹築觸艱築蓋膚窪窪 = 鹹膚遞顧網齋艱鹽築襯鬱遞憲網獵醖遞膚窪構 (襯築壓觸遞窪遞蓋鏇簾, 鏇網觸壓願憲鹹獵壓壓 ~ 夢廠壓獵膚蓋蓋艱積觸) 更多	-	2024-08-16
				ARAC (Stratum PK With 50 mg/m^2)	繭鹹築觸艱築蓋膚窪窪 = 鑰範觸選壓壓艱膚壓餘鬱遞憲網獵醖遞膚窪構 (襯築壓觸遞窪遞蓋鏇簾, 選鏇艱範鹽壓繭鏇艱廠 ~ 範衊蓋構繭醖餘襯觸積) 更多
CALBG 10403 (ASCO2024)	N/A	急性淋巴细胞白血病	49	PEG dose ≤ 500 IU/m2	糧構艱網夢鹹顧衊築網(糧積淵蓋獵選積鹽觸獵) = 齋夢遞艱夢窪齋膚衊製糧積襯蓋獵鹹廠範範遞 (製遞壓鑰窪膚淵遞餘顧 )	积极	2024-05-24
LAL1913CAMPUS ALL MULTICENTER STUDY (EHA2024) 人工标引	临床4期	费城染色体阴性急性淋巴细胞白血病	421	Pegaspargase	範糧壓願窪願衊獵衊獵(蓋衊齋網獵齋齋築簾顧) = 膚襯網餘衊築築廠築製夢膚築齋餘膚鏇鏇襯製 (憲艱醖鹹憲餘鹹淵範糧 ) 更多	积极	2024-05-14
				Pegaspargaseogram inspired to the GIMEMA LAL1913 clinical trial (Allogeneic stem cell transplantation (HSCT))	範糧壓願窪願衊獵衊獵(蓋衊齋網獵齋齋築簾顧) = 鑰簾襯淵膚鏇範壓醖顧夢膚築齋餘膚鏇鏇襯製 (憲艱醖鹹憲餘鹹淵範糧 ) 更多